Perry Brunette

Jurupa Valley, CA (USA)
Role(s):
Founder/Owner/Principal

PathFree Technologies Corporation

Find More Startups Startup
Location: Irvine
Industry: Technology/Web
Year Founded: 2021
Number Employees: 1-10 people
Business Stage: Growth (not profitable)
Entity Type: "C" Corporation
Description: My name is Dr. Perry M. Brunette, Ph.D., and I am reaching out to request your support in securing $10,000,000 to advance our groundbreaking technology, DataSyteAiCLS, through clinical trials, FDA clearance, and its subsequent launch to the global medical market. Introduction to DataSyteAiCLS DataSyteAiCLS is a revolutionary AI system designed to mimic the expertise of the world’s leading cardiologists, heart surgeons, and other medical specialists. Leveraging advanced deep learning algorithms and continuous feedback, DataSyteAiCLS is capable of mastering the intricacies of medical expertise, from diagnosing complex conditions to recommending precise surgical interventions. The Vision Behind DataSyteAiCLS At PathFree Technologies, we envision a future where AI-driven medical technology transforms healthcare delivery. Our goal is to develop AI systems that not only support but enhance the decision-making capabilities of medical professionals. DataSyteAiCLS represents a significant step toward this vision, promising to revolutionize the medical field with its unparalleled accuracy and efficiency. Key Features of DataSyteAiCLS Advanced Diagnostic Capabilities DataSyteAiCLS utilizes sophisticated deep learning techniques to analyze patient data and provide accurate diagnoses. By learning from a vast array of medical cases, the system can identify patterns and anomalies that might be missed by human practitioners. Precision in Surgical Recommendations One of the standout features of DataSyteAiCLS is its ability to recommend precise surgical interventions. The AI system can evaluate various treatment options, considering patient-specific factors to suggest the best possible approach. This ensures that patients receive tailored, optimal care. Continuous Learning and Improvement DataSyteAiCLS is designed to continually learn and improve from real-world data and feedback. This ensures that the system stays up-to-date with the latest medical knowledge and practices, maintaining its cutting-edge performance. Investment Opportunity PathFree Technologies is seeking $10,000,000 in funding through a Reg D 506c offering. This investment opportunity offers investors 50% of PathFree Technologies' profits for five years, along with the option to receive a return of capital or convert their position into equity shares of PathFree Technologies on a one-for-one basis. Benefits High Potential for Returns Investing in DataSyteAiCLS presents a significant opportunity for substantial returns. With the growing demand for advanced medical technology, the market potential for DataSyteAiCLS is immense. Equity Conversion Option Investors have the unique option to convert their investment into equity shares, allowing them to become part-owners of PathFree Technologies. This offers a long-term stake in the company’s future success. The Impact of Your Investment Revolutionizing Healthcare Your investment will play a crucial role in revolutionizing healthcare. By supporting DataSyteAiCLS, you are contributing to the development of a technology that can save lives, improve patient outcomes, and enhance the efficiency of medical practices worldwide. Driving Innovation Investing in DataSyteAiCLS means being at the forefront of medical innovation. Your support will help drive the clinical trials, FDA clearance, and global launch of a technology that has the potential to set new standards in healthcare. Enhancing Global Health Outcomes The global impact of DataSyteAiCLS cannot be overstated. By enabling accurate diagnoses and optimal treatment recommendations, the system can significantly improve health outcomes on a global scale. Your investment will help make this a reality. Next Steps We are excited about the transformative impact DataSyteAiCLS can have on healthcare and would be delighted to discuss this investment opportunity further with you. Your support is pivotal in bringing this groundbreaking technology to the market. Contact Information For more information or to discuss this investment opportunity, please contact: Dr. Perry M. Brunette, Ph.D. Email: (URL removed) Phone: (Phone # removed)Conclusion Thank you for considering this opportunity to be a part of a groundbreaking advancement in medical technology. Your investment in DataSyteAiCLS will not only provide substantial returns but also contribute to a future where AI-driven medical solutions enhance healthcare for all.